International Journal of Health Policy and Management

International Journal of Health Policy and Management

Multi-dimensional Perspective Pharmaceutical Evaluation: A Path to Enhancing Healthcare Decision-Making in Real-World

Document Type : Letter to Editor

Authors
Jinmiao Lu 1
Xiaohua Ying 2
Zhiping Li 1
1 Department of Clinical Pharmacy, National Children’s Medical Center, Children’s Hospital of Fudan University, Shanghai, China
2 NHC Key Laboratory of Health Technology Assessment, Department of Health Economics, School of Public Health, Fudan University, Shanghai, China
10.34172/ijhpm.2024.8295
Abstract
Multi-dimensional Perspective Pharmaceutical Evaluation: A Path to Enhancing Healthcare Decision-Making in Real-World
Keywords
Pharmaceuticals
Healthcare
Multi-Dimensional
Innovation
Regulation

Dear Editor,

 

China is one of the world’s largest producers of active pharmaceutical ingredients and generic drugs.1 In 2021, the Chinese government established a comprehensive evaluation system that defines the value of pharmaceuticals across six dimensions, including safety, efficacy, cost-effectiveness, appropriateness, accessibility, and innovation.2 Policy-makers and clinical specialists consider six criteria and their relevant sub-criteria in assessing the overall performance of drugs. Firstly, safety aspects encompass adverse drug reactions causing systemic damage and the incidence rate of individual adverse reactions. ...(Read more...)

  1. Socal MP, Ahn K, Greene JA, Anderson GF. Competition and vulnerabilities in the global supply chain for US generic active pharmaceutical ingredients. Health Aff (Millwood). 2023;42(3):407-415. doi:1377/hlthaff.2022.01120
  2. Lu J, Ying X, Li Z. Value-based generic drug evaluation focus on Chinese real-world evidence. Int J Health Policy Manag. 2023;12(1):7970. doi:34172/ijhpm.2023.7970
  3. China National Health Development Research Center. Technical Guidelines for Comprehensive Clinical Evaluation of Cardiovascular, Antineoplastic, and Pediatric Drugs. http://www.nhei.cn/nhei/znfb/202206/c01d87a290664b01bf42a9dad769d69f.shtml.
  4. Lu J, Wang G, Ying X, Li Z. A novel drug selection decision support model based on real-world medical data by the hybrid entropic weight TOPSIS method. Technol Health Care. 2023;31(2):691-703. doi:3233/thc-220355
  5. Sayah R, Awada S, Ismaiil L, Hatem G. Assessment of the differences between generic and biosimilar drugs: a brief literature review. J Generic Med. 2023;19(3):124-129. doi:1177/17411343231157309
  6. Russo P, Zanuzzi M, Carletto A, Sammarco A, Romano F, Manca A. Role of economic evaluations on pricing of medicines reimbursed by the Italian National Health Service. Pharmacoeconomics. 2023;41(1):107-117. doi:1007/s40273-022-01215-w
International Journal of Health Policy and Management
Volume 13, Issue 1
2024
Pages 1-3

  • Received Date 22 September 2023
  • Revised Date 16 January 2024
  • Accepted Date 13 February 2024
  • First Published Date 17 February 2024
  • Published Date 01 December 2024